Grann Pharmaceuticals is dedicated to developing mRNA lipid nanoparticle therapeutics for diseases associated with missing or deficient proteins. Our mission is to advance these investigational therapies through rigorous research and clinical development, with the goal of creating meaningful treatment options for patients and families facing serious unmet medical needs.
Our Mission
The Story Behind Grann
Grann Pharmaceuticals takes its name from “Grannan,” the grandmother of our founder and CEO, Thomas Lyle Temple. Her passing in September 2018 inspired a deeply personal commitment to improving the lives of patients and their families. Her legacy continues to shape our purpose: pursuing scientific advances with compassion, determination, and an understanding of the people behind every diagnosis.
The Challenge
Some genetic conditions disrupt the production or function of proteins essential to healthy development and everyday life.
Our Approach
We develop mRNA lipid nanoparticle therapeutics designed to deliver instructions that cells can use to produce a protein of interest.
Our Science
Explore the science behind our mRNA lipid nanoparticle platform and its application across our investigational programs.
Our Founder & CEO
Thomas Lyle Temple
Founder, President & Chief Executive Officer
Inspired by his grandmother, Thomas Lyle Temple founded Grann Pharmaceuticals to pursue new therapeutic approaches for diseases associated with genetic abnormalities and protein deficiency. He leads the company’s development of investigational mRNA lipid nanoparticle therapies, with RTT-1 for Rett syndrome as its lead program. His vision for Grann connects a personal commitment to patients with the scientific work needed to advance potential treatments.
Meet Our Founding Team
Left to right: Thomas Lyle Temple, President & CEO; Ishaan Chetty, VP & Head of QC & Operations; Dominic Samanta, VP & Head of Pre-Clinical Operations; Mason Lebby, CSO; Cole Irie, Head of Vivarium Operations
Connect With Grann
We welcome conversations with investors, scientific collaborators, clinicians, and patient communities across our areas of research. Contact our team about partnerships, our investigational programs, or other diseases of interest.